Optimizing Breast Cancer Care: The Patient Perspective_Sheila McGlown and Julia Maues

11:15

Mark Pegram, MD; Stanford Health Care; 5Live #SABCS20

6:13

Key insights from the 2020 Annual Breast meeting in San Antonio

Sara Hurvitz, MD, University of California Los Angeles; 5Live #SABCS20

6:30

Key insights from the 2020 Annual Breast meeting in San Antonio

Julie Gralow, MD, University of Washington, Seattle Cancer Care Alliance; 5Live #SABCS20

5:14

Key insights from the 2020 Annual Breast meeting in San Antonio

Erika Hamilton, MD; Sarah Cannon; 5Live #SABCS20

2:48

Key insights from the 2020 Annual Breast meeting in San Antonio

Bill Gradishar, MD, FASCO, FACP; Northwestern University; 5Live #SABCS20

5:23

Key insights from the 2020 Annual Breast meeting in San Antonio

Javier, Cortes, MD, PhD IOB Italy Institute of Oncology Quiron Group Madrid and Barcelona, Spain 5Live #ASCO20

5:10

Key Insights on KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemo vs placebo + chemo for previously untreated locally recurrent inoperable or metastatic TNBC

"Patrick Neven, MD, PhD Universitaire Ziekenhuizen Leuven, Belgium 5Live #ASCO20"

4:58

Key Insights on MONARCH 2: subgroup analysis of pts receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced BC

Hope S. Rugo Professor of Medicine; Director, Breast Oncology and Clinical Trials Education; UCSF Comprehensive Cancer Center 5Live #ASCO20

6:58

"Key Insights on Alpelisib + fulvestrant in PIK3CA-mutated HR+/HER2– advanced BC previously treated with CDK 4/6 inhibitor + aromatase inhibitor (AI): BYLieve study results "

Hope Rugo Professor of Medicine; Director, Breast Oncology and Clinical Trials Education; UCSF Comprehensive Cancer Center 5Live #ASCO20

6:09

"Key Insights on A phase Ib study of abemaciclib in combination with pembrolizumab for pts with HR+/HER2- locally advanced or MBC (NCT02779751): Interim results "